Last reviewed · How we verify
Sivelestat sodium hydrate
At a glance
| Generic name | Sivelestat sodium hydrate |
|---|---|
| Also known as | Elaspol |
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan (PHASE4)
- Effect of Neutrophil Elastase Inhibitor on Lung Injury After Esophagectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sivelestat sodium hydrate CI brief — competitive landscape report
- Sivelestat sodium hydrate updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI